Oncolines® Technology Platforms for Precision Oncology

Cell-Based Assays to Determine Genetic Drivers and Biological Pathways for Precision Oncology

Oncolines® Cancer Cell Lines, Proliferation Assays and Bioinformatics Analysis

  • Proliferation assays on a large panel of cancer cell lines aid in patient stratification biomarker discovery

  • Bioinformatics analysis on IC50 data and pharmacogenomics for biomarker discovery, drug sensitivity and targeting

SynergyFinder™ Screen for Synergistic Drug and Therapy Combinations

  • Determination of synergy for combination therapy by curve-shift analysis and CI values
  • Reference dataset of >180 compounds available
  • Hypothesis driven experiments as well as broad screening

Mechanistic Cell Biology, In Vitro Assays to Determine Mechanism of Action

  • Flexible assay development and screening,
  • Proof of concept studies, determination of mechanism of action
  • Testing of a wide range of cancer cells, immune cells and primary patient material in vitro

Efficient, Convenient, Secure Reporting

  • Primary data and final reports shared via a secured link

Continuous and High-Throughput Screening

  • Turnaround time starts at day of arrival of compounds at Oncolines and ends with transfer of final report and primary data

Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster

Oncolines offers a set of complimentary technologies to enable clients to determine the activity, selectivity and mechanism of action of drugs and drug candidates

  • Available on a fee-for-service basis and collaborations via an integrated precision medicine approach.

  • It is our mission to bring improved and novel therapies to the right patient population faster.